OpenEvidence gives doctors a free AI search tool for clinical evidence, helping them investigate questions around diagnosis and treatment. Axios, citing Business Insider, reported that the company raised $250 million at a $15 billion valuation.

The company’s TakeHome page describes a medical-content library that includes full-text clinical findings and figures from The New England Journal of Medicine and JAMA, along with treatment algorithms from the National Comprehensive Cancer Network. OpenEvidence brings those materials into a search workflow built for clinicians.

Access begins with professional eligibility rather than a subscription. STAT reported in January that a national provider identifier was enough for a clinician to use OpenEvidence without charge, while advertisements shown to clinicians supplied the company’s primary business model.

The latest account follows a separate $250 million financing OpenEvidence announced in January. STAT said Thrive Capital and DST Global led that round at a $12 billion valuation; the new reported mark is 25% higher after eight months, with the same headline amount raised.

Axios said undisclosed hospital systems invested alongside Andreessen Horowitz. The report did not name them or identify them as customers, so their participation should be read as an investment rather than evidence that hospitals have bought or deployed the product.